Silvercrest Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.4M Buy
13,666
+7,298
+115% +$7.46M 0.11% 253
2026
Q1
$5.86M Sell
6,368
-198
-3% -$201K 0.04% 405
2025
Q4
$7.06M Sell
6,566
-503
-7% -$481K 0.05% 385
2025
Q3
$5.39M Buy
7,069
+451
+7% +$336K 0.04% 417
2025
Q2
$5.16M Buy
6,618
+9
+0.1% +$6.99K 0.03% 426
2025
Q1
$5.46M Buy
6,609
+1,070
+19% +$890K 0.04% 394
2024
Q4
$4.28M Buy
5,539
+103
+2% +$85.3K 0.03% 443
2024
Q3
$4.82M Buy
5,436
+349
+7% +$314K 0.03% 388
2024
Q2
$4.61M Sell
5,087
-7
-0.1% -$5.6K 0.03% 411
2024
Q1
$3.96M Sell
5,094
-269
-5% -$191K 0.03% 430
2023
Q4
$3.13M Buy
5,363
+303
+6% +$177K 0.02% 442
2023
Q3
$2.72M Buy
5,060
+26
+0.5% +$13.4K 0.02% 445
2023
Q2
$2.36M Buy
5,034
+703
+16% +$295K 0.02% 461
2023
Q1
$1.49M Buy
4,331
+25
+0.6% +$8.43K 0.01% 508
2022
Q4
$1.58M Sell
4,306
-75
-2% -$26.6K 0.01% 508
2022
Q3
$1.42M Hold
4,381
0.01% 499
2022
Q2
$1.42M Sell
4,381
-20
-0.5% -$6K 0.01% 521
2022
Q1
$1.26M Sell
4,401
-289
-6% -$74.4K 0.01% 569
2021
Q4
$1.29M Buy
4,690
+7
+0.1% +$1.77K 0.01% 534
2021
Q3
$1.08M Buy
4,683
+1,760
+60% +$434K 0.01% 568
2021
Q2
$671K Sell
2,923
-1,495
-34% -$300K ﹤0.01% 627
2021
Q1
$825K Sell
4,418
-295
-6% -$57.7K 0.01% 597
2020
Q4
$796K Buy
4,713
+64
+1% +$9.56K 0.01% 566
2020
Q3
$688K Buy
4,649
+48
+1% +$7.43K 0.01% 557
2020
Q2
$755K Sell
4,601
-20
-0.4% -$3.07K 0.01% 546
2020
Q1
$641K Sell
4,621
-1,425
-24% -$196K 0.01% 539
2019
Q4
$795K Buy
6,046
+1,392
+30% +$161K 0.01% 551
2019
Q3
$520K Buy
4,654
+11
+0.2% +$1.23K ﹤0.01% 579
2019
Q2
$514K Hold
4,643
﹤0.01% 433
2019
Q1
$602K Sell
4,643
-15
-0.3% -$1.82K 0.01% 415
2018
Q4
$539K Sell
4,658
-2,485
-35% -$278K 0.01% 389
2018
Q3
$767K Buy
7,143
+112
+2% +$11.2K 0.01% 382
2018
Q2
$600K Hold
7,031
0.01% 401
2018
Q1
$544K Sell
7,031
-2,000
-22% -$161K 0.01% 413
2017
Q4
$763K Buy
9,031
+1,934
+27% +$165K 0.01% 383
2017
Q3
$607K Hold
7,097
0.01% 398
2017
Q2
$584K Sell
7,097
-84
-1% -$6.85K 0.01% 390
2017
Q1
$604K Sell
7,181
-2,500
-26% -$200K 0.01% 392
2016
Q4
$712K Buy
9,681
+1,500
+18% +$112K 0.01% 380
2016
Q3
$657K Hold
8,181
0.01% 378
2016
Q2
$644K Buy
8,181
+3,129
+62% +$236K 0.01% 379
2016
Q1
$364K Sell
5,052
-300
-6% -$22.7K 0.01% 439
2015
Q4
$451K Buy
5,352
+750
+16% +$62.2K 0.01% 431
2015
Q3
$385K Sell
4,602
-1,200
-21% -$101K 0.01% 392
2015
Q2
$484K Sell
5,802
-16,152
-74% -$1.23M 0.01% 403
2015
Q1
$1.59M Buy
21,954
+350
+2% +$24.9K 0.02% 286
2014
Q4
$1.49M Hold
21,604
0.02% 287
2014
Q3
$1.4M Hold
21,604
0.02% 290
2014
Q2
$1.34M Buy
21,604
+672
+3% +$40.1K 0.02% 294
2014
Q1
$1.23M Buy
20,932
+300
+1% +$16.7K 0.02% 293
2013
Q4
$1.05M Sell
20,632
-124
-0.6% -$6.21K 0.02% 309
2013
Q3
$1.04M Buy
20,756
+124
+0.6% +$6.49K 0.02% 299
2013
Q2
$1.01M Buy
+20,632
New +$1.12M 0.02% 294

Other funds holding LLY

Silvercrest Asset Management's LLY Position: Q2 2026 in Review

Silvercrest Asset Management increased its Eli Lilly (LLY) stake by 115% in Q2 2026, buying an estimated $7.46M and bringing the position to 13,666 shares worth $16.4M. The position accounts for 0.11% of the portfolio, ranked #253.

Silvercrest Asset Management first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Silvercrest Asset Management held 13,666 shares of Eli Lilly worth $16.4M as of Q2 2026.
  • Silvercrest Asset Management bought 7,298 Eli Lilly shares in Q2 2026, an estimated $7.46M.
  • Eli Lilly made up 0.11% of Silvercrest Asset Management's portfolio in Q2 2026, its #253 holding.
  • Silvercrest Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.